跳至主要内容
临床试验/ACTRN12613000331730
ACTRN12613000331730尚未招募4 期

A placebo-controlled, randomized, double-blind trial of the effects of modified release 4-aminopyridine (fampridine) on upper limb impairment in Multiple Sclerosis

Austin Health0 个研究点目标入组 60 人开始时间: 2013年3月25日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
Austin Health
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Multiple sclerosis; impaired upper limb function (NB this applies to the group of 40 patients; there will also be 20 healthy controls who are being included primarily for validation of electrophysiological measurements as there are no published normal values for these parameters.

排除标准

  • Age < 18 years; history of seizures or epilepsy; hypersensitivity to fampridine; moderate/severe renal impairment; pregnancy; current or recent (60 days) MS relapse; alternative likely cause for upper limb impairment (e.g. peripheral neuropathy, injury); current or recent (60 days) therapy with corticosteroids; current therapy with benzodiazepines; recent (within 60 days) addition of new therapy for multiple sclerosis including disease-modifying therapies and symptomatic therapies.

研究者

发起方
Austin Health

相似试验

已完成
1 期
A placebo-controlled, randomized, double-blind trial to investigate the impact of dapagliflozin on the development of diabetic ketoacidosis and intermediate metabolism in type 1 diabetes using a dual stable tracer method: A safety study investigating the fuel shift theory in the human modelE10Type 1 diabetes mellitus
DRKS00021284Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Abteilung für Endokrinologie und Diabetologie17
进行中(未招募)
1 期
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2020-000082-16-PLEsoCap AG42
进行中(未招募)
4 期
Can treatment with Cerebrolysin improve recovery after acute ischemic stroke?Radiologically confirmed acute ischemic stroke with onset within 72 hours prior to screeningCirculatory SystemAcute ischemic stroke
ISRCTN88122184The foundation for the study of neuroscience and neuroregeneration290
进行中(未招募)
1 期
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2020-000082-16-NLEsoCap AG42
招募中
2 期
A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitischronic inflammation of the esophagus10017969eosinophilic esophagitis
NL-OMON52665EsoCap AG10